Shares in ReNeuron (LON:RENE) rose sharply following an update on a Phase I clinical trial of ReNeuron’s CTX stem cell therapy for disabled stroke patients. There have been no cell-related or...
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
http://ift.tt/1JQgAIq @MasterMetals MasterMetals Blog
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
http://ift.tt/1JQgAIq @MasterMetals MasterMetals Blog
No comments:
Post a Comment
Commented on MasterMetals